Zhende Medical Co (SHSE:603301) Research & Development: ¥144 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603301 Zhende Medical Co Ltd SHSE:603301
53 GF Score
Price ¥81.24
GF Value ¥26.65
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Zhende Medical Co Research & Development?

Zhende Medical Co SHSE:603301 -3.46% 53 Research & Development is ¥144 Mil as of Jun. 2026. GuruFocus rates SHSE:603301 with a GF Score™ of 53/100 and a GF Value™ of ¥26.65 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Zhende Medical Co's Research & Development for the three months ended in Jun. 2026 was ¥34 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was ¥144 Mil.

Zhende Medical Co  (SHSE:603301) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Zhende Medical Co Research & Development Related Terms

Zhende Medical Co Research & Development Historical Data

* Premium members only.

The historical data trend for Zhende Medical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhende Medical Co Research & Development Chart

Zhende Medical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 153.14 227.00 138.95 135.49 142.43

Zhende Medical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.25 35.78 42.92 30.61 34.28
SHSE:603301
53GF Score
Zhende Medical Co Ltd SHSE:603301
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhende Medical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥144 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ¥144 Mil mean?
Zhende Medical Co (SHSE:603301) has a Research & Development of ¥144 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on Zhende Medical Co and its competitors.
Is Zhende Medical Co's Research & Development too high?
Zhende Medical Co's current Research & Development is ¥144 Mil. Overall, Zhende Medical Co has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zhende Medical Co's Research & Development compare to ISRG and BDX?
Zhende Medical Co's Research & Development of ¥144 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Zhende Medical Co and its competitors. Zhende Medical Co's current Research & Development is ¥144 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhende Medical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhende Medical Co (SHSE:603301) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥26.65, compared to a current price of ¥81.24 — trading 204.8% above its estimated fair value. The current Research & Development is ¥144 Mil. Zhende Medical Co's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Zhende Medical Co (SHSE:603301), the current Research & Development is ¥144 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhende Medical Co (SHSE:603301) Overvalued in 2026?

Based on GuruFocus' analysis, Zhende Medical Co stock appears to be overvalued. The current stock price of ¥81.24 is trading 204.8% above its estimated GF Value™ of ¥26.65. GuruFocus considers Zhende Medical Co to be Significantly Overvalued.

Key valuation signals for SHSE:603301:

  • Research & Development: ¥144 Mil
  • GF Value™: ¥26.65 vs. price of ¥81.24 (204.8% above fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the SHSE:603301 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zhende Medical Co Business Description

Address No. 55 Xiangji Road, Gaobu Street, Yuecheng District, Zhejiang Province, Shaoxing City, CHN, 312035
Zhende Medical Co Ltd operates as a supplier of medical care and protection in China. The company is engaged in the production and sales of medical dressings. Its product categories are basic medical dressings, operating room sensory control, pressure therapy and fixation, stoma and chronic wounds, Isolation protection, and personal protection.
53GF Score

Get the complete analysis for SHSE:603301

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥81.24
Price
¥26.65
GF Value